Pfizer, riding high on COVID-19 vaccine launch, pays CEO Bourla $21 million for 2020

By | March 12, 2021

Thanks to the success of its COVID-19 vaccine, the drug giant Pfizer has become a household name around the globe—and the company’s eyeing $ 15 billion in sales from the shot this year.

For writing that 2020 success story, CEO Albert Bourla collected a pay package worth more than $ 21 million.

Bourla, who took the reins as Pfizer’s CEO in early 2019, scored $ 21.03 million in total 2020 pay, a proxy filing submitted Friday shows. Bourla’s compensation package includes a salary of $ 1.65 million, cash incentive pay of $ 5.49 million and long-term incentive awards—in the form of Pfizer options that vest over time—of $ 14 million.

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.

For Pfizer—and the entire global economy—last year was defined by the COVID-19 pandemic. Thanks to its quick response and its vaccine partnership with BioNTech, the company now has a coronavirus vaccine very much in demand throughout the world.

The company quickly ushered its program through clinical testing last year, and in December the Pfizer/BioNTech shot scored the first FDA emergency use authorization for a COVID-19 vaccine.

RELATED: First-to-market Pfizer expects a whopping $ 15B from its COVID-19 shot in 2021

Now, the company is rolling out the shot in the U.S., Europe and elsewhere. Pfizer and BioNTech aim to produce 2 billion doses in 2021, and Pfizer has said it could see $ 15 billion—or more—in sales from the shot this year.

Read More:  Experts warn daily Covid cases could be as high as 45,000 in England

Aside from its work in COVID-19, Pfizer also completed its Upjohn spinoff last year. In July 2019, the company said it would combine the off-patent branded and generic established medicines business with generic giant Mylan. The deal closed last November, completing Pfizer’s push to transition into a research-based drugmaker.

RELATED: Pfizer’s big split is finally here, thanks to a giant generics merger with Mylan

Last year, during his first year as CEO, Bourla’s pay totaled $ 19.7 million. As chief operating officer the prior year, he nabbed a $ 9.85 million compensation package.

Bourla’s 2020 compensation comes in at about the middle of Big Pharma CEO pay packages reported so far. Johnson & Johnson’s Alex Gorsky pulled in nearly $ 30 million, for instance, while Eli Lilly CEO David Ricks’ pay package totaled $ 23.7 million. AstraZeneca CEO Pascal Soriot nabbed a $ 21.5 million compensation package.

Sanofi CEO Paul Hudson’s pay came in at $ 13.6 million last year, while Novartis’ Vas Narasimhan collected $ 11.6 million. GSK CEO Emma Walmsley’s 2020 pay came in at around $ 9.7 million.

FiercePharma: Pharma